Close Menu

Interpace Biosciences

The company's ThyGenX and ThyraMir tests are designed for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.

The agreement, which covers Interpace's ThyGenX and ThyraMIR diagnostic tests for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.

During the quarter, the firm secured payor coverage for its tests with UnitedHealthcare, Premera Blue Cross, and Aetna. 

Interpace Diagnostics said that the test will now be covered for Cigna's roughly 15 million members nationwide.

The deal with Aetna includes coverage for Interpace's ThyGenX oncogene panel and ThyraMir microRNA gene expression classifier.

The test is now covered by Premera Blue Cross, a regional health plan with more than 2 million members located primarily in Washington, Oregon, and Alaska.

The company raised net proceeds of $12.2 million, which it will use for various purposes, including working capital and payment of legacy obligations. 

The firm said it will use the proceeds for working capital, trade payables, payment of legacy obligations, and general corporate purposes.

The company said in an SEC document that it will offer about 6.3 million shares of its common stock. Some purchasers would also be able to buy prefunded warrants.  

The company will provide its molecular thyroid tests to researchers at Einstein Medical Center of Philadelphia.

Pages

Nebula Genomics will be auctioning George Church's genome as a nonfungible token, according to The Scientist.

Anthony Gregg, the outgoing president of the American College of Medical Genetics and Genomics, has resigned after using racially insensitive language. 

Facebook has developed an artificial intelligence approach to predict how drugs interact in cells, New Scientist reports.

In PNAS this week: adaptations among high-altitude Mycobacterium tuberculosis, response of multiple myeloma cells to chemotherapy-induced stress, and more.